Lv1
28 积分 2024-07-04 加入
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
10小时前
待确认
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
14天前
已完结
911 Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice
3个月前
已完结
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations
3个月前
已完结
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial
3个月前
已完结
Optimal Systemic Treatment and Real-World Clinical Application of ctDNA in Patients with Metastatic HER2-Mutant Lung Cancer
3个月前
已完结
AYVM to AYMM transition on HER2 exon 20 insertion induces TKI resistance in NSCLC
3个月前
已完结
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
3个月前
已完结
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia
3个月前
已完结
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)
3个月前
已完结
皖公网安备34019202002308
